drugset / Trial / NCT05923190
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.
Timeline
- Start
- 2023-06-14
- Primary completion
- 2028-07-01
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfortumab Vedotin | Other / unclassified | 1.25 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |